Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05261126 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 381
- Enrollment target
NCT05261126 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 381 participants.
The verdict
NCT05261126, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 381 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of enclitide chloride, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of the four doses of enclitide chloride tested in this study is superior to placebo on percent change from baseline in LDL-C at Week 8.
Interventions
- DRUG Placebo
- DRUG Enclitide Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2022-03-10 |
| Est. Completion | 2022-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05261126
The ClinicalTrials.gov registry entry for NCT05261126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 381 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05261126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05261126 about?
NCT05261126 is a clinical study titled "A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)". The purpose of this study is to evaluate the efficacy and safety of enclitide chloride, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of the four doses of enclitide chloride test...
What is the current status of trial NCT05261126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 381 participants. The study started on 2022-03-10. Estimated completion is 2022-11-28.
What interventions are being tested in trial NCT05261126?
The interventions under investigation include: Placebo (DRUG), Enclitide Chloride (DRUG).
Who is sponsoring clinical trial NCT05261126?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.